(:LJPC)

Aug 22, 2022 08:55 am ET
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer
Aug 01, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, LJPC, SMED
NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 28, 2022 09:48 am ET
LJPC Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of La Jolla Pharmaceutical Company Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of La Jolla Pharmaceutical Company (NASDAQ: LJPC) to Innoviva, Inc. for $6.23 per share in cash is fair to La Jolla shareholders.
Jul 27, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ZEN, LJPC, VIVO, PCSB
NEW YORK, July 27, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 26, 2022 07:12 pm ET
Lifshitz Law PLLC Announces Investigation of RFP, LJPC, ZEN and NEOG
Resolute Forest Products Inc. (NYSE: RFP) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RFP to The Paper Excellence Group, through its wholly-owned subsidiary Domtar...
Jul 26, 2022 02:09 pm ET
The M&A Class Action Firm is Investigating the Mergers of NEOG, LJPC, and XPOA
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 18, 2022 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates LJPC, ZEN, RFP, VHAQ
NEW YORK, July 18, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 16, 2022 01:14 am ET
Equity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPC
NEW YORK, July 16, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating La Jolla Pharmaceutical Co. (LJPC), relating to its proposed acquisition by Innovia, Inc. Under the terms of the agreement, LJPC shareholders are expected to receive $6.23 in cash per share they own. Click here for more information: http:
Jul 14, 2022 12:45 pm ET
LA JOLLA PHARMACEUTICAL COMPANY ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of LJPC and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of La Jolla Pharmaceutical Company (NASDAQ: LJPC) (“La Jolla”) breached their fiduciary duties or...
Jul 13, 2022 11:32 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ironSource Ltd. (NYSE - IS), Sharps Compliance Corp. (Nasdaq - SMED), La Jolla Pharmaceutical Company (Nasdaq -
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jul 12, 2022 01:42 pm ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, LJPC, FSI, SYRS
NEW YORK, July 12, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 11, 2022 11:44 pm ET
Jul 11, 2022 09:43 pm ET
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates LJPC, EURN, EMCF
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: La Jolla Pharmaceutical Company...
Jul 11, 2022 08:34 pm ET
LA JOLLA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of La Jolla Pharmaceutical Company - LJPC
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of La Jolla Pharmaceutical Company (NasdaqCM: LJPC) to Innoviva, Inc. (NasdaqGS: INVA). Under the terms of the proposed transaction, shareholders of La Jolla will receive only $6.23 in cash for each share of La Jolla that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jul 11, 2022 09:31 am ET
Thinking about buying stock in La Jolla Pharmaceutical, Toughbuilt Industries, Waitr Holdings, Sutro Biopharma, or Magnachip Semiconductor?
NEW YORK, July 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LJPC, TBLT, WTRH, STRO, and MX.
Jul 11, 2022 08:51 am ET
LJPC Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of La Jolla Pharmaceutical Company Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of La Jolla Pharmaceutical Company (NASDAQ: LJPC) to Innoviva, Inc. for $6.23 per share in cash is fair to La Jolla shareholders.
Jul 11, 2022 07:32 am ET
Innoviva to Acquire La Jolla Pharmaceutical Company
Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and
May 16, 2022 04:15 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress
Mar 09, 2022 08:15 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corp
Nov 17, 2021 08:00 am ET
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that it will commence a share repurchase plan for up to $10 million of the Company’s common stock. Repurchases may be made from time to time at the Company’s discretion. The plan has no time limit and can be discontinued at any time. There
Nov 04, 2021 08:45 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2021 and highlighted corpo
Sep 10, 2021 08:00 am ET
Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer.
Aug 05, 2021 08:30 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2021 and highlighted corporate p
May 07, 2021 08:45 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted co
Mar 08, 2021 08:55 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate
Jan 12, 2021 07:30 am ET
Thinking about buying stock in T2 Biosystems, Zomedica, Aldeyra Therapeutics, La Jolla Pharmaceutical, or US Well Services?
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, ZOM, ALDX, LJPC, and USWS.
Jan 12, 2021 07:00 am ET
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an
Nov 09, 2020 05:35 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020
On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase), a biopharmaceutical company focused on commercializing its novel tetracycline, XERAVATM (eravacycline), to treat serious and life-threatening infections, for $43 million in upfront cash plus potential future cash payments of up to $16 million. Financial results for periods ending September 30, 2020 and beyond include Tetraphase’s financial results subsequent to the acquisition closing date of July 28, 2020.
Aug 06, 2020 08:30 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for...
Jul 28, 2020 04:16 pm ET
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer. “Larry has an impressive track record bringing innovative treatments that address...
Jul 28, 2020 04:15 pm ET
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc....
Jun 24, 2020 07:30 am ET
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc....
Jun 05, 2020 10:40 am ET
Thinking about buying stock in Global Eagle Entertainment, Niu Technologies, TOP Ships, La Jolla Pharmaceutical, or Bank of America?
NEW YORK, June 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENT, NIU, TOPS, LJPC, and BAC.
May 04, 2020 08:30 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for...
Apr 13, 2020 08:30 am ET
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing...
Apr 07, 2020 08:30 am ET
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing...
Apr 06, 2020 08:30 am ET
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey,
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing...
Apr 03, 2020 08:30 am ET
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing...
Apr 02, 2020 08:30 am ET
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Guy’s and St. Thomas’ NHS Foundation Trust, Londo
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing...
Mar 13, 2020 08:00 am ET
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing...
Mar 02, 2020 08:30 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for...
Jan 09, 2020 08:00 am ET
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Nov 25, 2019 08:35 am ET
La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Nov 25, 2019 08:30 am ET
La Jolla Pharmaceutical Company Announces Management Transition
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Nov 12, 2019 04:47 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Sep 05, 2019 09:00 am ET
La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Aug 29, 2019 09:00 am ET
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Aug 01, 2019 08:00 am ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Jul 23, 2019 09:00 am ET
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Jun 28, 2019 06:30 am ET
La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Jun 06, 2019 09:00 am ET
La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 06, 2019 04:11 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Apr 24, 2019 09:00 am ET
La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Apr 08, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Advanced Micro Devices, Syros Pharmaceuticals, La Jolla Pharmaceutical, Integer, Mesoblast, and InnerWorkings — What Drives Growth in Today's Competitive La
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Advanced Micro Devices, Inc. (NASDAQ:AMD), Syros Pharmaceuticals, Inc....
Mar 11, 2019 07:30 am ET
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Mar 07, 2019 04:01 pm ET
La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Mar 04, 2019 04:01 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Feb 25, 2019 04:04 pm ET
La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Feb 14, 2019 07:18 pm ET
La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on GIAPREZA (angiotensin II) at the Society of Critical Care Medicine’s (SCCM) 48th Critical Care Congress to be held February 17 - 20, 2019 in...
Feb 05, 2019 08:20 am ET
Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Re
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ArcBest Corporation (NASDAQ:ARCB), International Game Technology...
Jan 07, 2019 09:00 am ET
La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today highlighted...
Jan 04, 2019 09:00 am ET
La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Nov 06, 2018 08:35 am ET
Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Exelon Corporation (NYSE:EXC), La Jolla Pharmaceutical Company...
Oct 24, 2018 04:01 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Oct 18, 2018 04:01 pm ET
La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Oct 16, 2018 07:25 am ET
Recent Analysis Shows Professional Diversity Network, Quanex Building Products, HTG Molecular Diagnostics, La Jolla Pharmaceutical, Playa Hotels & Resorts N.V, and Plexus Market Influences — Renewed O
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Professional Diversity Network, Inc. (NASDAQ:IPDN), Quanex Building...
Aug 16, 2018 08:00 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion Corporation (NASDAQ:CLSN), Alpha and Omega Semiconductor Limited...
Aug 08, 2018 04:01 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Aug 03, 2018 09:00 am ET
La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Aug 01, 2018 05:39 pm ET
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Jun 25, 2018 09:00 am ET
La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II)
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 21, 2018 08:25 am ET
Recent Analysis Shows Engility, La Jolla Pharmaceutical, Freshpet, At Home Group, Denny's, and SP Plus Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Engility Holdings, Inc. (NYSE:EGL), La Jolla Pharmaceutical Company...
May 17, 2018 01:00 pm ET
La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 10, 2018 04:46 pm ET
La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners
La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today...
May 10, 2018 04:45 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 01, 2018 05:15 pm ET
CalciMedica Names Two Senior Executives to its Board of Directors
LA JOLLA, Calif., May 1, 2018 /PRNewswire/ -- CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger, JD, MBA, a co-founder and Chief Business Officer of Escalier Biosciences. The two new Board members bring extensive clinical development and financing/transaction experience, respectively, to CalciMedica as it advances its novel acute pancreatitis agent, CM4620, through clinical development.
Mar 23, 2018 07:40 am ET
Market Trends Toward New Normal in La Jolla Pharmaceutical, AquaVenture, Duluth, Community Bank System, Cubic, and TrustCo Bank Corp NY — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of La Jolla Pharmaceutical Company (NASDAQ:LJPC), AquaVenture...
Mar 22, 2018 04:01 pm ET
La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by the U.S. Food and Drug Administration (FDA) to...
Mar 15, 2018 08:00 am ET
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing...
Mar 14, 2018 04:01 pm ET
La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced a registered...
Mar 06, 2018 02:40 pm ET
GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018
Feb 25, 2018 09:00 am ET
GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine’s 47th Critical Care Congress
Feb 22, 2018 05:17 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for...
Feb 21, 2018 09:00 am ET
La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for intravenous infusion, in...
Jan 24, 2018 08:00 am ET
Consolidated Research: 2018 Summary Expectations for Freshpet, eHealth, SEACOR, La Jolla Pharmaceutical, Rogers, and On Assignment — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Freshpet, Inc. (NASDAQ:FRPT), eHealth, Inc. (NASDAQ:EHTH),...
Dec 21, 2017 06:15 pm ET
La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)
Giapreza increases blood pressure in adults with septic or other distributive shock
Dec 18, 2017 09:00 am ET
La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human hepcidin) in patients with hereditary...
Dec 04, 2017 09:00 am ET
La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical study of LJPC‑401 (synthetic human hepcidin) in patients with transfusion-dependent beta thalassemia...
Oct 26, 2017 05:10 pm ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and nine months ended September 30, 2017

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.